About
Novel Therapeutic Approach for the Treatment of B-cell Malignancies
BARcure provides a therapeutic platform applicable to various B-cell neoplasms, primarily non-Hodgkins lymphoma (NHL). The company is currently focusing on the development of two BAR-based products for the treatment of DLBCL and MCL. BARcure specifically targets malignant B cells with novel immunotherapies designed to kill tumor cells while sparing normal B cells. The company leverages the robust research work done by Prof. Michael Pfreundschuh from Saarland University in Germany.
Identity
| Name | BARcure |
|---|---|
| Slug | barcure |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoK3kp4wIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Apr 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | |
| HQ address | Ilan Ramon St 2, Ness Ziyyona, Israel |
Web & social
| Website | http://barcure.co.il/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
biopharmaceuticalimmunologytherapeuticsdrug-deliverycancerpharmaceuticalsimmuno-theraphyoncologyimmunotherapy
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}